Fig. 1

Trial schema. After enrollment (Visit 1) participants are allocated to test sequences A or B. Visits 2 and 3 form Stage I of the trial, which was to quantify the immediate and naïve effects of Keeogo™ on physical performance tests in a clinical setting by comparing test performance with (cW) and without (cWO) using Keeogo™. During Stage II of the trial, participants used Keeogo™ at home for 2 weeks (hW) and for 2-week without (hWO) Keeogo™. Participants were monitored all 4 weeks using an Actigraph activity monitor, in order to quantify the effects of Keeogo™ on physical activity levels. Clinical testing at mid-way (Visit 4) and post (Visit 5) was used to quantify any changes in participants physical performance with (cW) or without (cWO) Keeogo™ resulting from home usage